NASDAQ: $EYPT A Major Milestone in Retinal Disease Treatment EyePoint Pharmaceuticals has officially announced the topline results from its LUCIA study, the second pivotal Phase 3 clinical trial evaluating the efficacy and safety of DURAVYU (vorolanib) for the treatment of wet age-related macular degeneration (wet AMD). Understanding the LUCIA Trial Results The LUCIA trial was…

NASDAQ: $EYPT A Potential Breakthrough for Wet AMD EyePoint Pharmaceuticals has shared promising topline results from the LUGANO clinical trial, the first of two pivotal Phase 3 studies evaluating the efficacy and safety of Duravyu™ (EYP-1901). Designed as a potential treatment for wet age-related macular degeneration (wet AMD), this investigative therapy is being studied as…